Ayurcann Holdings Corp. · OTC:AYURF
Ayurcann — Investor Presentation (May 2024)
23 slides from Ayurcann's investor presentation, May 2024
Slide 1: An Innovative World Of Cannabis
An Innovative World Of Cannabis Investor Presentation May 2024 ayurcann.com
Slide 2: © 2023 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only.
General Saskatchewan Investors right of action for rescission is exercisable not later than 180 days from the date on which payment is made for the securities. If a purchaser elects to The information contained in this presentation has been prepared by Ayurcann Inc. ( Ayurcann ) in connection with t
Slide 3: Making quality a priority by achieving high standards
Making quality a Delivering consistency Top tier innovation priority by achieving with speed and and value without the high standards premium prices. every time. you can count on. Experience the difference with AYURCANN – Quality, Reliability and Affordability – We ve got it all. © 2023 Ayurcann Inc
Slide 4: Market Opportunity and High Opportunity For Growth
Market Opportunity YoY Revenue Growth Recreational Brands Over High Opportunity For Growth Unique SKU s © 2023 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only. 3
Slide 5: Ayurcann Estimated Cannabis Segment Sales Growth
AYURCANN ESTIMATED CANNABIS SEGMENT SALES GROWTH * - Milled Flower - Pre-rolls - Vape Cartridges - Total Market Share *Source: Marijuana Factbook & Cannabis Manufacturers Guild © 2023 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only. 4
Slide 6: Canadian cannabis market size
$10.4B $5.4B 202 2 2025 *Source: Stats Canada and equity research. © 2023 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only. 5
Slide 7: Gross Revenue | Year-Over-Year
Gross Revenue | Year-Over-Year 65% Projected Growth 101% Growth $37M** Growth 1176% Growth Total Gross Revenue Earned | Not including projections** $611k 2020 2021 2022 2023 Gross Revenue Projected Annual Run Rate** © 2023 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only.
Slide 8: Canada Wide Distribution
Canada Wide Distribution Current Canadian distribution has Ayurcann continues to push more access to a total of 3186 retail stores. products in the various provinces on a continious basis. ALBERTA 750 retail stores BRITISH COLUMBIA 480 retail stores SASKATCHEWAN 103 retail stores ONTARIO 1600 retail
Slide 9: Store Penetration and Total Products
83.3% Store Penetration 50% Store Penetration 46 Total Products SKUs available in over 67 Stores 42 Total Products 57% Store Penetration 23 Total Products 60% Store Penetration 100% Store Penetration SKUs available in over 235 Stores 55% Store Penetration SKUs available in over 29 Stores 7 Total Pro
Slide 10: Over 60 Unique SKUs
Over 60 Unique With the success of pre-rolls and vapes, Ayurcann is focused on enhancing our offerings by entering #1 Best Selling 2x1g Pre-rolls the infused pre-roll categories. in Ontario **As of April 27th, 2023 per Hifyre and OCS Combining our best-selling pre-rolls with our best-selling vapes.
Slide 11: Provincial market share
MB British Columbia NB 55% Alberta ON SK Sasketchewan Manitoba Ontario AB BC New Brunswick 5% © 2023 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only. 10
Slide 12: Upcoming Product Launches in 2024
Only Years Selling Recreationally Upcoming Product Launches in 2024 Solidified Brands © 2023 Ayurcann Inc. All rights reserved. Confidential for discussion purposes only. 11
Slide 13: Total Sales - Continuing to Grow
Total Sales - Continuing to Grow Quarter-Over-Quarter $12,000,000 $11,000,000 $10,000,000 $9,000,000 $8,000,000 $7,000,000 $6,000,000 $5,000,000 $4,000,000 $3,000,000 $2,000,000 $1,000,000 602K Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2020 2020 2021 2021 2021 2021 2022 2022 2022 2022 2023
Slide 14: Fire up your day!
F ir e u p yo u r d a y ! *Information gathered from Trellis and Hifyre
Slide 15: *Information gathered from Trellis and Hifyre
*Information gathered from Trellis and Hifyre
Slide 16: Happy & Stoned Summer 2024
a HAPPY & STONED 38 HAPPY & STONED ¢ « | HAPPY & STONED { 6 | SUMMER 2024 HAPPY é& STONED
Slide 17: Annual and quarterly revenue highlights
2021 2022 2023 2024 Q1 2024 Q2 2024 (end Jun 30) (end Jun 30) (end Jun 30) • REVENUE: $11.79mm growth • REVENUE: $10.74m growth for the period increase of for the period increase of • REVENUE: $7.65mm growth of • REVENUE: $11mm growth of • REVENUE: $22.37mm growth 240% gross revenue. 141% gross reve
Slide 18: Management and Directors
Management and Directors Igal Sudman Roman Buzaker Jaspreet Bhatia, Phd Raj Virk, M.sc CEO and Co-founder, Director President, COO and Co-founder, Director Quality Control Manager Quality & Compliance Manager Mr. Sudman is a business development Mr. Buzaker is a corporate strategist Mrs. Bhatia is a
Slide 19: Directors
Directors Alison Gordon David Hackett Maor Shayit Director Director Director A veteran of the cannabis industry, Alison has Mr. Shayit is a seasoned and ambitious operations worked in all verticals of this emerging market. Mr. Hackett brings more than 20 years of financial & marketing professional w
Slide 20: Transaction Highlights
Transaction Highlights Closing Pro-Forma Offering Size Valuation On Cash SPAC Management Team Ownership1 Condition • Arogo Capital Acquisition Corp. • The combined enterprise ~78.83% existing Ayurcann No minimum cash on Suradech Taweesaengsakulthai (NASDAQ:AOGO) is a publicly value of Ayurcann and i
Slide 21: Transaction Summary
Transaction Summary SOURCES USES SPAC Cash in Trust(1) $19,647,685 Cash to Company Balance Sheet $10,453,231 PIPE(2) - Seller Rollover Equity $210,000,000 Seller Rollover Equity(3) $210,000,000 Transaction Expenses(4) $9,149,454 Total Sources $229,647,685 Total Uses $229,647,685 Pro Forma Shares Out
Slide 22: Valuation Benchmarking
Valuation Benchmarking Enterprise Value / Revenue EV / Revenue (2026) 2025 2026 Pre-money valuation at $210M Avg 2.88x Avg 2.65x 3.76x 1.85x 1.63x 2.62x 2.46x 2.43x 4.65x 5.06x 4.85x 2.22x 2.04x 1.72x 1.64x Enterprise Value / EBITDA EV / EBITDA (2026) Pre-money valuation at $210M Avg 12.02x Avg 11.3
Slide 23: Thank You!
Thank You! Contact Us Igal Sudman CEO and Co-founder 905.492.3322 IR@ayurcann.com ayurcann.com